Skip to Content
Merck

SML2844

Rivaroxaban

≥98% (HPLC), selective factor Xa (FXa) inhibitor, powder

Synonym(s):

(S)-Rivaroxaban, (S)-5-Chloro-N-{[2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]oxazolidin-5-yl]methyl} thiophene-2-carboxamide, 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide, BAY 59-7939, BAY-59-7939, BAY59-7939, 5-Chloro-N-[[(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]-2-thiophenecarboxamide

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C19H18ClN3O5S
CAS Number:
Molecular Weight:
435.88
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Product Name

Rivaroxaban, ≥98% (HPLC)

Quality Level

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -34 to -44, c = 0.3 in DMSO

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

[s]1c(ccc1C(=O)NC[C@@H]2OC(=O)N(C2)c3ccc(cc3)N4CCOCC4=O)Cl

InChI

1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1

InChI key

KGFYHTZWPPHNLQ-AWEZNQCLSA-N

Biochem/physiol Actions

Rivaroxaban is an orally active, active site-targeting, highly potent and selective factor Xa (FXa) inhibitor (IC50 = 0.7 nM; no activity against thrombin, trypsin, plasmin, FVIIa, FIXa, FXIa, urokinase, or activated protein C up to 20 μM) with good anticoagulant activity in vitro (dose for doubling fibrin formation time = 230/300 nM in human/rat plasma) and antithrombotic efficacy in vivo (ED50 = 1 mg/kg i.v. or 5 mg/kg p.o. by rat arteriovenous shunt model).


Still not finding the right product?

Explore all of our products under Rivaroxaban


pictograms

Environment

hcodes

Hazard Classifications

Aquatic Chronic 2

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



C Weinz et al.
Xenobiotica; the fate of foreign compounds in biological systems, 35(9), 891-910 (2005-11-26)
The pharmacokinetics of BAY 59-7939 - a novel, oral, direct Factor Xa inhibitor - were investigated in rats and dogs in support of preclinical safety studies and clinical development. BAY 59-7939 was rapidly absorbed after oral dosing, with an absolute
Georges Jourdi et al.
Thrombosis research, 183, 159-162 (2019-11-05)
Clinical benefit-risk balance of direct oral anticoagulants (DOAC) in atherothrombosis prevention differs between anti-Xa and anti-IIa drugs and their specific effect on platelet functions remains controversial. We hence investigated rivaroxaban and dabigatran effect on platelets in identical experimental conditions. Blood
Bart J Biemond et al.
Thrombosis and haemostasis, 97(3), 471-477 (2007-03-06)
Current anticoagulant therapies for the prevention and treatment of thromboembolic disorders have many drawbacks: vitamin K antagonists interact with food and drugs and require frequent laboratory monitoring, and heparins require parenteral administration. Oral rivaroxaban (BAY 597939) is a new, highly



Global Trade Item Number

SKUGTIN
SML2844-25MG04061842334551
SML2844-5MG04061842334568